Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage LYON, France and NEWTON, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today...

Alizé Pharma 3 change de nom pour Amolyt Pharma, illustrant sa stratégie de développement d’un portefeuille de peptides thérapeutiques pour les maladies endocriniennes et métaboliques rares LYON, France et NEWTON, Mass., 02 juin 2020 (GLOBE NEWSWIRE) -- Alizé Pharma 3, une société internationale spécialisée dans le développement de peptides thérapeutiques pour le traitement de...

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and Metabolic Diseases LYON, France and NEWTON, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Alizé Pharma 3, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today...